Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 2
2007 1
2008 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Lorusso V, Crucitta E, Silvestris N, Rosati G, Manzione L, De Lena M, Palmeri S, Gebbia V, Mancarella S, Sobrero A, Pezzella G, Comella P, Mangiameli A, Muci D; Italian Bladder Cancer Group. Lorusso V, et al. Among authors: muci d. Oncol Rep. 2005 Feb;13(2):283-7. Oncol Rep. 2005. PMID: 15643512 Clinical Trial.
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
Frasci G, Nicolella G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Natale M, Piantedosi F, Russo A, Palmeri S, Comella G, Panza N. Frasci G, et al. Among authors: muci d. Br J Cancer. 2001 May 4;84(9):1166-71. doi: 10.1054/bjoc.2001.1741. Br J Cancer. 2001. PMID: 11336465 Free PMC article. Clinical Trial.
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials.
Comella P, Gambardella A, Frasci G, Avallone A, Costanzo R; SICOG investigators. Comella P, et al. Crit Rev Oncol Hematol. 2008 Feb;65(2):164-71. doi: 10.1016/j.critrevonc.2007.06.014. Epub 2007 Aug 16. Crit Rev Oncol Hematol. 2008. PMID: 17702595 Clinical Trial.
Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Russo A, Palmeri S, D'Aniello R, Giordano R, D'Aiuto M, Comella G; Southern Italy Cooperative Oncology Group. Frasci G, et al. Among authors: muci d. Oncology. 2005;68(2-3):223-9. doi: 10.1159/000086778. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015038 Clinical Trial.